SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-156011
Filing Date
2023-05-30
Accepted
2023-05-30 07:34:59
Documents
14
Period of Report
2023-05-30
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d506633d8k.htm   iXBRL 8-K 32927
2 EX-99.1 d506633dex991.htm EX-99.1 15294
6 GRAPHIC g506633img001.jpg GRAPHIC 10861
  Complete submission text file 0001193125-23-156011.txt   190890

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akba-20230530.xsd EX-101.SCH 2835
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20230530_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20230530_pre.xml EX-101.PRE 10802
8 EXTRACTED XBRL INSTANCE DOCUMENT d506633d8k_htm.xml XML 3279
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 23971402
SIC: 2834 Pharmaceutical Preparations